JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266839

Human MYL6B (MLC1SA) knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

MYL6B KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp insertion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
1 Images
Sanger Sequencing - Human MYL6B (MLC1SA) knockout HEK-293T cell line (AB266839)
  • Sanger seq

Unknown

Sanger Sequencing - Human MYL6B (MLC1SA) knockout HEK-293T cell line (AB266839)

Homozygous : 2 bp insertion in exon 2

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 2 bp insertion in exon 2

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266839-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266839 Human MYL6B (MLC1SA) knockout HEK-293T cell line", "number":"AB266839-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266839-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266839-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266839-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266839 Human MYL6B (MLC1SA) knockout HEK-293T cell line", "number":"AB266839-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266839-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266839 Human MYL6B (MLC1SA) knockout HEK-293T cell line", "number":"AB266839-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266839-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266839 Human MYL6B (MLC1SA) knockout HEK-293T cell line", "number":"AB266839-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
MYL6B
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

MLC1SA also known as myosin light chain 1 slow-twitch muscle isoform plays a significant role in muscle contraction. It binds to myosin heavy chains in muscle fibers regulating the actin-myosin interaction essential for muscle contraction. MLC1SA has a molecular mass of approximately 18 kDa and shows expression predominantly in slow-twitch muscle fibers which are important for endurance activities. It also exhibits expression in certain cardiac tissues highlighting its function beyond skeletal muscles.
Biological function summary

MLC1SA contributes to muscle contraction regulation by modulating the interaction between actin and myosin. It is part of a complex that includes myosin heavy chains and other associated proteins. Through phosphorylation events MLC1SA adjusts the sensitivity of muscle fibers to calcium which is critical for the fine-tuning of muscle responses to stimuli. This subtle modulation is important for activities that rely on sustained muscle tension.

Pathways

Myosin light chain signaling involves MLC1SA as a central component in muscular contraction pathways. It plays a role in the myosin-actin crossbridge cycle aiding the efficient conversion of ATP into mechanical work. MLC1SA interacts with other proteins such as myosin heavy chains and calmodulin. These interactions are critical in pathways like the calcium signaling pathway and muscle contraction pathway where calcium ions serve as triggers for changes in muscle cell activity.

Defects or alterations in MLC1SA expression or function can relate to muscular dystrophies and myopathies. These conditions often involve muscle weakness and reduced endurance where MLC1SA disruption alters normal muscle function. Moreover cardiomyopathies can show links with this protein especially when considering the interaction with myosin heavy chains and tropomyosin. Alterations in these interactions may disrupt cardiac muscle contraction contributing to disease pathogenesis.

Quality control

STR analysis

D16S539, TPOX, CSF1PO, D13S317, D7S820, D5S818, TH01

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com